Circulating miR-186-5p is an emerging biomarker for acute coronary syndrome (ACS) patients.However, its kinetic signatures and prognostic values in ACS patients undergoing percutaneous coronary intervention (PCI) remain unclear.Levels of serum miR-186-5p were determined in 96 healthy controls and Electronics - Watches 92 ACS patients before and after PCI by qRT-PCR, and the physiologic state of miR-186-5p was analyzed by comparing its absolute concentrations in isolated exosomes and exosome-depleted supernatants.An average of 1 year of follow-up for ACS patients after PCI was performed.MiR-186-5p levels in the myocardium and serum of rats following left anterior descending coronary artery (LAD) ligation were measured.
Serum miR-186-5p levels were found to be significantly increased in ACS patients upon admission compared with those of controls, but these high miR-186-5p levels gradually decreased within 1 week after PCI.Serum miR-186-5p was mainly present in an exosome-free form rather than membrane-bound exosomes.Within 1 year of follow-up, ACS patients with higher miR-186-5p levels upon admission exhibited a higher incidence of MACE after PCI.Different statistical analyzes further validated the independent prognostic values of serum miR-186-5p in ACS patients after PCI.Serum miR-186-5p levels in rats following LAD ligation were increased, and there was a decrease in myocardial miR-186-5p levels.
Kyoto encyclopedia of genes and genomes (KEGG) analysis was performed to predict the related pathways of target genes Nipple Shield of miR-186-5p, which suggested that miR-186-5p might be involved in ACS by regulating the inflammatory status and D-glucose metabolism.In conclusion, a distinctive expression signature of serum miR-186-5p may contribute to monitoring the clinical condition and assessing the prognosis of ACS patients undergoing PCI.